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ABSTRACT

Spasticity can be one of the most challenging problems for patients with neurologic
conditions such as cerebral palsy, spinal cord injuries, cerebrovascular accidents, multiple
sclerosis, traumatic brain injuries, etc. It can lead to a wide variety of problems including
decreased mobility, decreased quality of movement, interference with normal postural
reactions, interference with functional activities, and pressure sores. Therefore, the
medical community has focused on effective treatments for spasticity which do not
produce overwhelming weakness, spasticity, paralysis, fatigue, and/or muscle atrophy.
Since the late 1970's, the use of botulinum toxin (BTX-A) injections to decrease spasticity
has been investigated.
The purpose of this paper is to review research studies involving the use of BTX-A
injections for the management of spasticity arising from central nervous system
dysfunction. This review will focus specifically on: (1) the effectiveness of BTX-A in
decreasing spasticity, and (2) improvements in functional performance and quality of life
due to this decrease in spasticity (including increased mobility, increased quality of
movement, and increased independence in activities of daily living).
In the majority of studies reviewed, significant decreases in spasticity upon injection of
BTX-A were reported. These decreases in spasticity caused subsequent increases in active
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and passive range of motion, and decreases in pain and uncontrolled movements.
Improvements in ambulation, transfer skills, hygiene skills, positioning ease, and overall
function were less frequently examined, but reported in approximately half of the studies
reviewed. Few studies mentioned the changes in quality of life or the increased ability in
carrying out role functions in daily life following BTX-A injections. Additional research
studies are needed to quantify the effects of BTX-A injections on functional limitations and
on quality of life. If research shows that patients obtain improved function following BTXA injections, physical therapy may be paramount in helping clients recognize their newly
found skills. The role of physical therapy following BTX-A injections is an area that
warrants additional research.
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CHAPTER 1
INTRODUCTION

Spasticity is an intriguing phenomena which spans an array of diagnoses and
ages. It can be one of the most challenging problems for patients with neurologic
conditions such as cerebral palsy, spinal cord injuries, cerebrovascular accidents,
multiple sclerosis, traumatic brain injuries, etc.' Glenn and Whyte' describe
spasticity as a
" ... syndrome associated with a persistent increase in the involuntary
reflex activity of a muscle in response to stretch. Four specific
phenomena may be variably observed in the constellation of
spasticity: hypertonia (frequently velocity-dependent and
demonstrating the "clasp-knife" phenomenon), hyperactive deep
tendon reflexes, clonus, and spread of reflex responses beyond the
muscle stimulated."
The primary consequence of spasticity is abnormal postural tone, a phenomena
resulting in an exaggerated array of spontaneous motor activity.2 Spasticity may
ultimately lead to a wide variety of problems including decreased mobility,
decreased quality of movement, interference with normal postural reactions,
interference with functional activities, and development of pressure sores. 3
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Experimental studies in animals suggest that the tone increase associated with
spasticity may interfere with longitudinal muscle growth and cause sustained
reduction of the anatomical muscle length. 4,s This may result in the conversion of
dynamic contractures to fixed permanent contractures.
Although the characteristics and causes of spasticity differ across various
neurologic conditions, the ultimate goal for rehabilitation professionals is to
maximize overall functional performance for individuals with abnormal postural
tone. Abnormal postural tone refers to the "abnormal reflexes and neuromuscular
signs associated with impaired movement."2 To maximize function, Perry6
contended that rehabilitation must emphasize the following areas: (1) contracture
minimalization, (2) realistic planning, (3) muscle-strength preservation and
restoration, (4) enhancement of returning control, (5) substitution for permanent
functional loss. Therapeutic approaches include casting, splinting, positioning,
physical modalities, motor learning/relearning, orthopaedic procedures, etc. 1,3
Physicians focus on the development of effective treatments for spasticity.
Active function will assumingly increase with reduction of spasticity, as long as the
treatment does not produce overwhelming weakness, paralysis, fatigue and/or
muscle atrophy.1 With effective management of spasticity, soft tissue contractu res
can also be prevented. Existing procedures utilized by physicians include
pharmacological management (oral baclofen, diazepam, benzodiazepine, sodium
dantrolene, phenothiazine), neurosurgical procedures (anterior and posterior
rhizotomy, selective posterior rhizotomy, cordotomy, intrathecal chemotherapy),
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phenol or baclofen injections, and nerve blocks. 1,3
It has been argued that the treatment procedures currently being employed are
unsatisfactory in the successful management of spasticity. Medications often
produce harmful side effects such as sedation and generalized weakness, and
cannot be used to selectively reduce harmful spasticity in one muscular area while
preserving useful spasticity in another.6-9 Neurosurgical procedures and nerve
blocks are invasive, non-selective, irreversible, and there is a chance that the
spasticity will re-occur. Intrathecal phenol injections are non-selective, and
complications may include incontinence, paresthesia, excessive weakness, and
even death.lO The conservative techniques utilized in physiotherapy to control
spasticity are often unsuccessful and temporary.
Physicians and therapists question whether the reduction of spasticity
automatically results in improved functional performance. 2 For example, many
children with cerebral palsy continue to move using irregular movement synergies
even after they have undergone selective posterior rhizotomies. If a treatment is
successful at reducing spasticity but does not increase functional performance,
critics question its legitimacy. An easily administered treatment which successfully
controls spasticity and increases functional performance is desired.
Since the late 1970's, the use of botulinum toxin (BTX-A) injections to decrease
spasticity has been investigated. 11 It was originally proposed for the correction of
strabismus, and is now considered the drug of choice for treatment of the following
conditions: hemifacial spasm, torticollis, essential blepharospasm, and spastic
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dysphonia. 12 Additional pathologies that are managed with BTX-A injections
include spastic torticollis, postural tremors, focal dystonias, and other limb
dystonias. Possible advantages of intramuscular BTX-A injections for the
management of spasticity include the lack of sensory effects, ability to target specific
muscle groups, ability to weaken muscles in a graded fashion, and absence of
caustic chemicals.
The purpose of this paper is to review research studies involving the use of
botulinum toxin injections for the management of spasticity arising from central
nervous system dysfunction. This will enable the researcher to address the
following issues: (1) the effectiveness of BTX-A in decreasing spasticity, and
(2) improvements in functional performance due to this decrease. Functional
performance includes, but is not limited to, increased mobility, increased quality of
movement and increased independence in activities of daily living.
This study closely follows the format utilized by Campbell et al 2, regarding the
effects of intrathecally administered baclofen on function in patients with spasticity.
Campbell et aF utilized a model developed at the National Center for Medical
Rehabilitation Research (NCMRR) to determine the functional effects of intrathecally
administered baclofen. The dimensions of the NCMRR model include:
(1) pathophysiology, (2) impairments, (3) functional limitations, (4) disabilities. The
effects of BTX-A will be examined utilizing these four dimensions of the NCMRR
model. A review of the literature on BTX-A injections will be conducted and
arranged according to the four dimensions developed by the NCMRR.

CHAPTER 2
PATHOPHYSIOLOGY

Pathophysiology of Spasticity
The NCMRR model describes pathophysiology as the "cellular and molecular
process of injury or disease pertinent to a particular condition".2 The
pathophysiology of spasticity is complex and varies among neurological conditions.
Spasticity is a distinct type of hypertonia in which there is a velocity-dependent
opposition to the passive movement of muscles.13,14 The faster the muscle is
stretched, the more resistance is encountered. Spasticity results from the
reorganization of spinal cord reflexes released from the brainstem or cortex, and is
due to disease and/or injury to the central nervous system. 14 In the individual
without spasticity, the nervous structures within the pyramidal tract exert
monosynaptic control over anterior horn cells for refined movements, and influence
tone through actions on brainstem nuclei. Thus, the brainstem, which is primarily
responsible for unrestrained, primitive reflexes, is controlled through the intricate
actions of the motor cortex, basal ganglia, and cerebellum. These areas are no
longer in control in the individual with spasticity, resulting in partial or entire
brainstem dominance.

5
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If brainstem dominance occurs, and primitive reflexes are uninhibited, the
stretch reflex arc becomes deprived of its normal supraspinal modulation. 6,13 This
results in pathological overactivity in stretch reflex circuits (i.e. exaggerated stretch
reflexes). For reasons not completely understood, sensory inputs and lack of
supraspinal control result in excessive activation of alpha motoneurons controlling
muscle contraction. 2 Hypertonic muscles are the result of this activation.
Theoretically, drugs which can be used to interfere with the abnormal reflex arc
and depress excessive activity of the muscle fibers are desirable.13 However, side
effects and long-term effects must be taken into careful consideration.13 Functional
performance can be hindered by those antispasticity drugs producing weakness,
paralysis, fatigue and/or muscle atrophy.

Characteristics and Actions of Botulinum Toxin Type-A (BTX-A)

Ingested orally, botulinum toxin causes fatal neuromuscular paralysis and is one
of the most potent biological poisons known. 15 The botulinum toxin utilized
commercially, Oculinum, is derived from the type A strain of Clostridium
Botulinum. 16 These gram-positive, rod-shaped, spore-forming, anaerobic bacteria
are a family of serologically related neurotoxins including A, B, C1, D, E, F, and

C.17 Clinically, the unit dose of BTX-A is based on a mouse LDso equivalent, that is,
the amount of toxin which kills 50 percent of a group of 18-20 mice.17,lB Each vial
of BTX-A contains 100 mouse units (MU) which is the median lethal dose for a 20
gram Swiss Webster mouse. On the basis of data obtained in monkeys, it has been
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estimated that the lethal dose for humans is 625 to 6,250 MU for an adult weighing
110 Ibs. There have been no reported instances of systemic toxicity resulting from
injections of botulinum toxin. 18
During the 1970's, extensive research was conducted on botulinum toxin
leading scientists to a better understanding of its mechanism of action.17 It was
recognized that the type A toxin could be utilized clinically to selectively paralyze
muscles. In fact, scientists discovered it produced a long-term blockade that was
very similar to surgical denervation, causing muscle paralysis, atrophy, and
electromyograph ic abnormal ities. 17
Early studies conducted by Drachman and Price 15 focused on quantifying the
mechanism of action of botulinum toxin. They discovered that "the action of
botulinum toxin is not due to deficient storage of acetylcholine in vesicles or
blockade of calcium entry into nerve terminal. Studies suggest that the toxin
. interferes with the acetylcholine process itself, possibly by blocking exocytosis at
the release sites." It is now known that BTX-A acts by inhibiting presynaptic
acetylcholine release at the cholinergic nerve terminals
without destroying nerve
,
endings, nerve terminals, or neuromuscular junctions. 17
To thoroughly explain how BTX-A produces its paralyzing effects, it is necessary
to review normal neuromuscular conduction. Normal neuromuscular conduction
involves the following steps 19 (see Fig. 1): (1) depolarization of the alpha
motoneuron causing propagation of an action potential down the nerve axon, (2)
conduction of the action potential to the nerve telodendria, which has vesicles
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Fig. 1 - "Normal" nerve conduction (adapted from Mohr19). A, shows depolarization
of the alpha motoneuron causing propagation of an action potential (AP) down the
nerve axon; B, conduction of the AP to the nerve telodendria, which has vesicles
storing the acetylcholine (ACh) neurotransmitter; C, influx of calcium into the
telodendria causing binding of vesicles to the presynaptic membrane; D, ACh
release into the synaptic cleft which binds to receptors on the motor end plate
membrane. This causes a motor end plate potential and a muscle AP is generated.
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storing the acetylcholine neurotransmitter, (3) influx of calcium into the telodendria
causing binding of vesicles to the presynaptic membrane, (4) release of
acetylcholine into the synaptic cleft, which binds to receptors on the motor end
plate and causes a motor end plate potential, and (5) generation of a muscle action
potential with ultimate contraction of the muscle. The inhibitory action of
botulinum toxin is believed to occur in three steps (see Fig. 2): (1) irreversible and
rapid binding of the toxin to specific presynaptic receptors on the peripheral
cholinergic synapses, (2) internalization of the toxin-receptor complex across the
presynaptic membrane, and (3) inhibition of acetylcholine release by disrupting the
calcium ion-mediated release of acetylcholine. 18 Consequently, BTX-A effectively
reduces hyperactivity, producing a functionally denervated muscle, and decreases
the excessive alpha motoneuron activity which is responsible for spasticity.
The results of a study conducted by Shaari and Sanders20 provided evidence that
injecting BTX-A at or near the motor end plate region of the muscle produces the
most effective paralysis. Maximal paralysis of the spastic muscle occurs several
days after injection. 16 The resulting paralysis is dose-dependent and reversible over
time, thus, repeat injections are required. The action of botulinum toxin persists for
approximately three months in most conditions, with some reported effects lasting
up to one year. It is believed that muscle recovery is due to intramuscular collateral
axon sprouting, which plays a major role in re-establishing the integrity of
neuromuscular transmission. Botulinum toxin binds rapidly to the receptors at the
neuromuscular junctions of the target muscles, therefore, little or no systemic
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Fig. 2 - Mechanism of action of botulinum toxin (adapted from Koman 18); A shows
irreversible binding of botulinum toxin (BTX-A) to specific presynaptic receptors on
the peripheral cholinergic synapses; B, internalization of the toxin-receptor complex
across the presynaptic membrane; C, the inhibition of ACh release by disruption the
calcium ion-mediated release of ACh.
10
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absorption of the toxin occurs.18
Scott21 was the first to utilize BTX-A therapeutically. After conducting initial
experiments on non-human primates, he successfully employed BTX-A injections in
the nonoperative management of strabismus.
The National Institute of Neurological Disorders and Stroke, and the Office of
Medical Applications of Research of the National Institutes of Health, convened a
consensus development conference to officially evaluate the clinical uses of BTX-A
therapy in November 1990. 22 After presentations and discussions by experts in the
field of botulinum toxin therapy, the panel issued a statement which covered the
following areas: mechanisms of action, indications and contraindications, safe and
effective uses, side effects and complications, and further research needs. The
panel emphasized that botulinum toxin therapy is an invasive, potent, irreversible
treatment, and should only be administered by licensed, experienced physicians.
Contraindications to its use include allergy to the drug or infection/inflammation at
the injection site(s). Side effects to BTX-A are usually transitory, well tolerated, and
treatable.

CHAPTER 3
RESEARCH CONDUCTED ON BOTULINUM TOXIN'S
EFFECTS ON IMPAIRMENTS
The NCMRR model described impairments as "derangements of organs and
organ system functions that directly result from the injury or disease process.,,2
Most of the studies conducted on botulinum toxin described its effects on the
musculoskeletal system, specifically, its effects on abnormal postural tone. This
included spasticity, pain as a result of spasticity, range of motion, strength,
uncontrolled and abnormal movements, spasms, and extremity
position i ng. 3,4,7, 11, 12,25-31

Botulinum Toxin's Effects on Spasticity,
Spasms, Pain, and Uncontrolled Movements
Das and Park23 were the first to study the effects of botulinum toxin injections on
spasticity.

The Oswestry scale 24 (see Table) was utilized to determine whether

eight patients with post-stroke spastic hemiplegia had decreased upper extremity
spasticity after injection of BTX-A into the following muscles: biceps, flexor
digitorum profundus and flexor carpi ulnaris. The Oswestry scale was designed to
be administered by experienced physical therapists. The patients responded well to
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Clinical Rating Scales
Oswestry Scale
0solely spasticity, no willed movement possible
1very severe spasticity, movement very poor
2severe spasticity, movement poor
3moderate spasticity, movement fair
4mild spasticity, movement good
5no spasticity, movement normal
The Degree of Adductor Tone
0no increase in tone
1increased tone, hips easily abducted to 45 degrees by one person
2hips abducted to 45 degrees with mild effort
3hips abducted to 45 degrees by one person with major effort
two people required to abduct the hips to 45 degrees
4Modified Ashworth Scale
o - no increase in tone
1slight increase in muscle tone, manifested by a catch and release or by
minimal resistance at the end of the range of motion when the affected
part(s) is moved in flexion and extension
1 ++ slight increase in muscle tone, manifested by a catch, followed by
minimal resistance throughout the remainder (less than half) of the ROM.
2more marked increase in muscle tone through most of the ROM, but affected
part(s) easily moved.
3considerable increase in muscle tone, passive movement difficult
4limb rigid in flexion or extension
Spasm
01234-

Frequency Scale
no spasms
1 or fewer spasms per day
between 1 and 5 spasms per day
5 to less than 10 spasms per day
10 or more spasms per day, or continuous contraction

13
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the injections, and were affected most noticeably at the flexor digitorum profundus.
One patient increased from a score of "1" on the Oswestry scale to a score of "4" .
Another patient increased from a score of "2" to a score of "5".
Aside from the research conducted by Das and Park 23 , few studies focused
specifically on the effects of botulinum toxin injections to decrease upper extremity
spasticity. Memin et aP' injected BTX-A into the upper extremity muscles of eight
patients with severe, longstanding spasticity. Although no formal spasticity scale
was utilized, all eight of the patients experienced a subjective decrease in spasticity,
and reported that this decrease in tone was "beneficial". Utilizing a visual analog
scale, five patients reported significant pain relief due to decreased spasticity.
Snow and colleagues 4 were the first to conduct a double blind study evaluating
the effects of BTX-A. The spastic adductor muscles of nine patients with multiple
sclerosis were injected. Two physicians independently assessed the patients
utilizing the Degree of Adductor Tone Scale devised by the researchers (see Table).
The results indicated that BTX-A toxin significantly reduces leg adductor spasticity
in multiple sclerosis (p

=

0.009). This decrease in spasticity resulted in a significant

improvement in the ease of nursing care (p

=

0.009). In two patients, one nurse

was able to perform care that required two nurses before injection. In another
patient, a chronic perineal excoriation became accessible to treatment and was
successfully healed.
Benecke 25 found similar results in his study of 14 patients with multiple sclerosis.
The patients had prominent, disabling spasticity of their adductor muscles and were
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chair-bound or bed-bound. Following the first BTX-A injections, spasticity, spasms
and pain were significantly decreased (p

<

0.001). The pain scores, based on a

subjective scale ranging between 0 (no pain) and 3 (severe and continuous pain),
were profoundly decreased. The global functioning score, calculated by summing
patient scores for spasticity, spasms, and pain for all patients, improved significantly
following BTX-A injection (p

< 0.001).

The majority of researchers studying BTX-A employed the modified Ashworth
scale26 (see Table) to measure and report patient spasticity scores before and after
toxin injection. In a study conducted on 10 patients with spastic drop foot, eight
patients had decreased spasticity in the injected calf muscles by one to two points. 27
Four of these patients who complained of pain became pain-free after the injections.

In another study, the soleus, tibialis posterior, and both heads of the gastrocnemius
muscles were injected in 12 patients with plantar flexor spasticity.28 Eighty-three
percent of the patients experienced a reduction of calf muscle spasticity after
injection, and six of the subjects had decreased achilles tendon clonus. An ankle
foot orthosis was no longer needed by one patient and was used to a lesser degree
in four subjects.
The results from a study of 12 patients with upper and lower extremity spasticity
indicated that every patient who was injected (eight patients in the lower extremity
muscles, four in the upper extremity muscles) demonstrated a "significant reduction
of tone" based on the Ashworth scale. 29 These patients also experienced
improvements of movement and posture, and five patients with severe painful
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spasms noted a decrease in the number and intensity of the spasms. Konstanzer et
al 30 found similar results; 10 of the 11 patients injected with the toxin showed an
increase of at least one point on each of the following: Ashworth scale, pain scale,
and hygienic scale (see Table).
Case studies were utilized by two researchers to illustrate the effectiveness of
BTX-A. Borg-Stein et aP provided case studies of two patients with chronic
progressive multiple sclerosis. Subject one had severe adductor spasms which
interfered with sleep and caused scissoring during standing. Oral baclofen and
dantrolene sodium provided only limited relief of the patient's spasticity. Two
months after BTX-A injection, the patient reported no more spasms at night. The
subject's adductor tone, based on the Degree of Adductor Tone Scale, decreased
from a "4" to "2" (see Table). The patient's spasm frequency score decreased from a
"3" to a "1" (see Table).7 Polo and Jabbari 12 reported a case study involving a patient
with "painful cramping" and involuntary movements of the left thigh, which were
refractory to a wide range of therapeutic treatments. The patient experienced a
complete control of pain, a notable reduction of abnormal leg movements, and a
distinct decrease of the burst discharges on the EMG for five months following BTXA injection into the left quadracep region.
The largest series of cases studied was reported recently by Dunne et al. 31 Forty
patients with moderate to severe spasticity of the upper or lower limbs who were
unresponsive to conventional physical and medical treatments were injected with
BTX-A. Clinical videotape assessments of spasticity were utilized and outcome
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measures included Ashworth spasticity and spasm frequency scales (see Table). The
mean change in the Ashworth spasticity score and the spasm frequency scale was

1.2 and 2.4 respectively, which indicated a significant decrease in spasticity and
muscle spasms (p

<

0.0001). Pain was reduced in 28 of the 31 patients. Overall, a

worthwhile benefit occurred in 85% of the patients, and these patients expressed
the desire to receive the treatment again if necessary.
Recently, several research studies have focused on the effectiveness of
botulinum toxin injections for children with spastic cerebral palsy.4,32,33 Cosgrove et
al 4 studied 26 subjects with cerebral palsy, and found that tone was clinically
decreased in the injected muscles (calves and hamstrings) in all but one patient.
One child with athetosis had a marked reduction in uncontrolled movements, and
his parents and physiotherapists reported decreased athetosis in his other limbs as
wel/.
Koman et aP2 divided 27 pediatric patients with cerebral palsy into the following
groups: three non-ambulatory patients with painful paraspinal spasticity which
interfered with sitting balance, eight non-ambulatory children with lower extremity
spasticity which interfered with positioning and hygiene, and 16 ambulatory
patients with spastic hemiplegia or diplegia. The two groups of non-ambulatory
patients were injected with BTX-A to decrease spasticity in order to reduce pain and
to facilitate positioning and hygiene. The last group of patients were injected with
the toxin to improve their gait. Caregivers reported that the children with painful
paraspinal muscle spasticity "rested more comfortably and could be positioned
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more easily after the BTX-A injections." Pain was reduced in all three children. The
eight children with lower extremity spasticity exhibited markedly reduced spasticity
and improved positioning. One patient who could not tolerate bracing before the
injection was successfully braced after the injection.
Calderon-Gonzales et aP3 utilized the Ashworth scale to quantify the change in
spasticity after BTX-A injection. Fifteen children with cerebral palsy were included
in the study, and it was found that the post-injection scores of muscle hypertonia
were significantly lower (P

<

0.01) than the pre-injection spasticity scores. The

decrease in hypertonicity persisted for four to six months. The movements most
significantly changed were hip adduction and knee flexion. Calderon-Gonzales and
colleagues suggested that in a young child, selective BTX-A injection may allow
sufficient time to regain muscle length before spasticity returns, thus preventing
contractu res and deformities.

Botulinum Toxin's Effects on Passive Movement, Active Movement, and Strength

Along with a decrease in spasticity, many patients experienced a increased range
of motion in muscles injected with BTX_A. 4,5,23,27,31,33,34 Das and Park23 found that all
eight of their subjects had increased elbow and wrist active and passive range of
motion after injection. One patient gained an additional 110 degrees of active and
160 degrees of passive motion at the elbow joint. Wall et aP4 also studied the
effect of BTX-A on upper extremity range of motion. Specifically, the potential of
BTX-A for the treatment of the thumb-in-palm deformity in patients with cerebral
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palsy was studied. Silhouette tracings were utilized to show that increased hand
range of motion after injection improved the hand positions in all five patients.
Although these patients had decreased grip strengths initially after the injection,
their grip dynamometry scores actually surpassed baseline levels by day 112.
Increased passive mobility has been anecdotally reported following injection of
botulinum toxin in two studies involving children with cerebral palsy.s,33 Following
BTX-A injection into the calf muscles of 23 children, Cosgrove et al s determined
that 74% of their patients had increased passive ankle dorsiflexion, with younger
patients displaying a greater increase than the older patients. In the same study, 21
hamstring muscles of 14 patients were injected with BTX-A and, on average, an
extra 20 degrees of passive extension was gained at the knee (p

< 0.01).

Calderone-Gonzalez and colleagues 33 found similar significant increases of passive
range of motion (p

< 0.001) in their patients after BTX-A injections.

Dunne and colleagues 31 used goniometer measurements and blinded videotape
assessments to determine increases of passive and active lower extremity range of
motion after BTX-A injection. Goniometer measurements showed a significant
increase in passive range of joint motion (p

< 0.0001), with an

average gain of 28

degrees. Blinded videotape assessments were based on a zero to four point scale
(zero

=

limb rigid in flexion; four

=

norma!), and indicated significant

improvements in both passive range of motion (p
motion (p

<

< 0.0001) and active range of

0.0002). Seventy-five percent of the patients showed at least a one

grade improvement in passive range of joint motion. Improved active movement
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scores in the lower limbs influenced personal hygiene, transfers, walking, and
allowed for more comfortable limb positioning.
Researchers have hypothesized that resolving lower extremity spasticity wi II
consequentially increase voluntary range of motion and have a variety of positive
results, however, few studies have systematically evaluated the effects of botulinum
toxin on active voluntary movement. 2 Cosgrove and colleagues 4 utilized gait
analysis to determine the effect of BTX-A on active movement. Following injection
of BTX-A into spastic calf muscles, there was an average increase of 11 degrees of
active dorsiflexion (p

<

0.05). This improvement of active dorsiflexion allowed

better ground clearance and more normal patterns of ankle kinematics during gait.
Following injection of BTX-A into 21 spastic hamstring muscles, patients were able
to fully extend their knees during late stance. The differences between active knee
extension before and after injection proved significant (p

< 0.01), and there was a

mean 22 degree gain in knee extension .
Dengler et aj27 also evaluated the effects of BTX-A injections on active voluntary
movement. Ten patients with spastic drop foot were treated, and passive and active
range of motion values were taken before and after the injection using a
goniometer. Seven patients showed an improvement of the drop foot position at
rest and an increase in passive dorsiflexion. Of the patients who were assessed for
freedom of active range of motion, four revealed an increase of active movement by
an average of eight degrees. Four patients showed an improvement of resting
supination position and nine showed an improvement of passive pronation in the
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lower ankle joint. Four patients showed increased active pronation by an average
of 11 degrees, and three patients had an increased range of active movement
(supination-pronation) by an average of 10 degrees. Active supination was
weakened by the toxin in the remaining three subjects.

CHAPTER 4
RESEARCH CONDUCTED ON BOTULINUM
TOXIN'S EFFECTS ON FUNCTIONAL LIMITATIONS
Functional limitations are defined as "problems with activities of the total body
or body segments as a result of impairments; they mayor may not be permanent,
depending on the course or resolution of the inciting process.,,2 Numerous
researchers have included anecdotal reports of changes in functional limitations as a
result of BTX-A injection, including positive changes in gait4,18,27,28,31-33, mobility and
function 3,4,23,28,29,31,34, efficiency of transfers and positioning3,32, and ease and
efficiency of hygiene skills.3,7,11,30

Botulinum Toxin's Effects on Gait

Several researchers have emphasized the changes in gait as a result of BTX-A
injections. Hesse et al 28 provided the most comprehensive study of changes in gait.
Gait analysis was utilized to focus on the following variables: velocity, cadence,
stride, stance symmetry, swing symmetry, double support times, and force
trajectories under the affected and non-affected foot. Following BTX-A injection,
velocity, stride length, stance symmetry, and length of the trajectory under the
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affected foot improved significantly (p

< 0.01). Cadence, double support times,

and the trajectory under the non-affected foot also improved, but did not fulfi II the
chosen significance level of p

=

0.01. Seven patients demonstrated better loading

and push off of the affected limb, and nine patients demonstrated better initial
contact of the affected limb. As a result of a longer stride length due to reduced
ankle muscle tone, gait velocity notably improved by a mean of 27% for the patient
group. The reduction of plantar-flexor spasticity improved the length of the force
trajectories under both feet, and increased the progression of body and stride length
during ambulation.
Mezaki et aP5 reported variable effects on the gait of three patients with spastic
paraparesis following BTX-A injection. Two patients had improved gait, however,
the effect was shortlived. Mezaki et aP5 attributed this transient effect to
compensation by the non-injected muscles for the muscles which were weakened
upon BTX-A injection. In the third patient, BTX-A injection into the quadriceps
caused a weakness with exacerbation of gait disturbance. Borg-Stein et al 3 also
found varied results. They discovered that following injection of the adductor
muscles in a subject with a "classic" scissored gait pattern, the patient was able to
walk between parallel bars without scissoring for the first time in several months.
Two months later, however, the patient reported a new inability to walk between
parallel bars, which was attributed to knee buckling.
Dunne and colleagues 31 reported that 10 patients had improved gait pattern and
five patients returned to walking following BTX-A injections into lower extremity

24

musculature.

Lindmark's modified motor assessment system 36, which assesses

active movements, repetitive movements, and mobility of all limbs, was utilized to
measure motor function. It was reported that following BTX-A injection, the
mobility of 27 patients was significantly increased (p

=

.007). Dengler et al 27 also

noted improvements in gait after injection into the calf musculature of ten patients
with spastic drop foot. The changes in stance and gait were evaluated by
physiotherapists. Among the six ambulatory patients, three revealed a "remarkable"
and two a "moderate" improvement in gait. This improvement in stance and
mobility was attributed to the improvement of joint mobility following BTX-A
injection.
All of the studies reviewed involving children with cerebral palsy included
qualitative measures of gait before and after botulinum toxin injection. 5,18)2,33 In
two separate studies, Koman et aP8,32 utilized several different measures to assess
lower-extremity function including gait analysis, physical therapy evaluation,
Biodex evaluation, physician rating scale (PRS), and parent/guardian questionnaire.
Preliminary results indicated that all of the patients, except for one child with a
fixed contracture, showed changes in tone of injected muscles. The PRS, which
measures degree of crouch, degree of equinus foot, position of hindfoot, position of
knee, speed of gait, and pattern of gait, increased from an average pretreatment
score of 5.0 to an average post-treatment score of 10.3. This proved a significant
increase (p

< 0.05) and was indicative of improved gait dynamics. Koman and

associates 18 utilized a randomized double blind trial for the follow-up study.
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Independent physical therapy evaluations of gait analysis films suggested that BTX-A
treatment improved gait as compared to placebo injections. Biodex measurement
proved to be an inappropriate evaluation tool for children with cerebral palsy. Posttreatment PRS scores showed an improved gait pattern in 83% of the patients, and
the parents/guardians of four of the six children receiving toxin reported that their
child's gait had improved during the trial.
Cosgrove and colieagues S utilized electrogoniometric measurements of sagittal
plane kinematics at the hip, knee, and ankle to assess gait in children with cerebral
palsy. Nine of the 19 patients who had potential for gait improvements
experienced a one to two-level progression in ambulatory status. Three patients
who were classified as "non-functional" ambulators became "functional"
ambulators. After six months, six patients continued to have a higher ambulatory
status than before the toxin injection. Resolution of spasticity with injection into the
calf and hamstring musculature allowed for better clearance of the foot during the
swing phase of gait and increased extension of the knee during the stance phase of
gait. Calderone 33 found similar results in three children who received injections
into their gastrocnemius muscles. These patients were able to achieve active heelstrike during gait.
Botulinum Toxin's Effects on Mobility and Function

Several research studies included data on the effects of botulinum toxin on
mobility and function. 3,4,23,27,28,32)3 Utilizing the Barthel index, which was
developed to assess functional independence before and after treatment, Das and
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Park23 recorded the functional abilities of a sample of ten patients with spasticity
associated with stroke-related hemiplegia. The test was given every two weeks
post-injection, and repeated measurements showed "some" improvement of
functional status. Increased independence in self-care and mobility skills in six
patients was also observed. The majority of patients increased their pre-injection
Barthel index score by 10- 15%.
Hesse et al 28 employed the Rivermead Mobility Index (RMI) to assess leg and
trunk motor function pre- and post-botulinum toxin injection. The RMI is an
evaluation tool used to measure physical recovery and progress following a stroke.
Two weeks after the injection, the Rivermead score increased by one point in three
patients and by two points in one patient. One patient was able to tap with the
non-affected foot five times while standing on the affected foot. Two patients could
achieve dorsiflexion of the ankle with the knee partially flexed and two could
achieve this with an extended knee.
Wall and colleagues 34 utilized comprehensive videotape assessments to
determine if BTX-A injections in patients with cerebral palsied hands improved
gross and fine motor functions. Function of the affected hand was compared with
function of the unaffected hand in the following tasks: tube transfer pronated, barrel
opening, card transfer, peg transfer, and overall function. Appearance of the hands
. was judged from still photographs in five standard positions including: (1) prone, (2)
midposition, (3) attempted supination, (4) maximum finger and thumb extension in
prone position, and (5) fisted. The overall functional and cosmetic improvement
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gained after BTX-A injection was found clinically significant (p

=

0.06), and

persisted throughout the follow-up time of 229 days. "Overall function" and
"overall appearance" were increased by as much as 43% and 64% respectively, and
were expressed as percentages compared to the function and appearance of the
unaffected limb. Parent and teacher reports indicated that the subjects increased
the spontaneous use of the affected hand both at "work" and at play. Wall et aP4
concluded that even if re-injection was required on an annual basis to attain
constant chemodenervation, BTX-A injection of the adductor pollicis is a safe,
appropriate alternative to surgical release.
Calderone-Gonzales et al 33 and Cosgrove et al 4 reported the effects of BTX-A
injections on functional outcomes in patients with cerebral palsy. CalderoneGonzalez and associates 33 measured the functional improvements of six patients on
the basis of their upright standing positioning. Six children who demonstrated
severe scissoring during standing were injected in their adductor muscles. The
scissoring tendency during standing "practically disappeared" in all six children. Six
children were injected in their knee flexor muscles and were able to straighten their
knees fully. Likewise, their body posture improved due to a more upright trunk and
reduced hyperflexion of the hip. Two patients improved in their weight bearing
ability and were able to initiate unassisted gait. One patient who was injected in
the posterior tibial muscle improved in varus deviation by 80%, and another patient
who was injected in the wrist flexor muscles was able to place his hand flat on the
table with wrist dorsiflexion. This enabled the patient to tolerate a wrist brace for
the fi rst ti me.
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Cosgrove and colleagues 4 provided subjective data to illustrate the functional
changes of 26 patients with cerebral palsy. Fourteen children were reported by
their parents to have displayed "marked" functional improvement, 10 reported a
"moderate" improvement, one reported "no change", and one reported a "moderate
deterioration". Based on subjective reports, 92% of the children experienced a
functional gain following BTX-A injection.
Borg-Stein et aP reported a case study describing the functional gains
experienced by a patient whose right hamstring musculature was injected with BTXA. During the eight month interval following injection, her short sitting ability
increased from five-and-a-half minutes of static sitting with assistance to more than
30 minutes of sitting while performing dynamic upper extremity activities.

Botulinum Toxin's Effects on Ease and Efficiency
of Transfer Skills, Positioning, and Hygiene Skills
Following a pilot study conducted on two patients with severe leg adductor
spasticity, Snow and colleagues 7 found that injection of BTX-A is a useful adjunct in
overall nursing care. They concluded that botulinum toxin is potentially more
beneficial for patients with isolated muscle contractions than "traditional" systemic
drug treatment. Potential applications include: treatment for patients with adductor
spasticity making care of the perineum difficult, treatment for patients at risk of softtissue necrosis between the legs, and treatment for patients with flexion and
adduction of the hip causing necrosis over the femoral head.
Konstanzer and colieagues 30 utilized the hygienic rating scale to determine the
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efficacy of botulinum toxin injections. Ninety-one percent of the patients injected
experienced an improvement of at least one point in hygienic scales. Memin et al ll
concluded that "most of the patients reported a benefit in their limb tone and
referred to a subjective improvement in the activity of daily life and nursing
following injection". Borg-Stein et aP discussed a patient who experienced
increased ease of abduction for catheterization, and became independent in
cleaning and catheterization.
The effects of BTX-A injections on the ease of positioning and transfers was
reported by several researchers. 3,12,32 Koman and colleagues 32 found that the three
children injected with BTX-A into spastic paraspinal musculature rested more
comfortably and could be positioned more easily. The nonambulatory children
with spastic lower extremities also experienced improved and more comfortable
positioning post-injection. Borg-Stein et aP discussed a patient whose spasms
inhibited effective transfers. Eight months following BTX-A injection into the right
hamstrings, the patient progressed from use of a Hoyer lift to sliding board transfers
with assistance. However, following injection of BTX-A into the bilateral hip
adductors, the subject noted increased difficulty with hip flexion in preparation for
bridging. Polo and Jabbari 12 described the effective treatment of an unusual
movement disorder with injection of BTX-A. Reduction of the constant movements
experienced by a patient with painful limb myoclonus enabled easier extremity
positioning and improved rest.

CHAPTER 5
BOTULINUM TOXIN'S EFFECTS ON DISABILITY IN ROLE FUNCTIONS

The NCMRR model defines "disabilities" as "difficulties in fulfilling the typical
role functions of daily life in the home, school, workplace, and community.,,2 The
studies reviewed did not attempt to measure changes in quality of life, or report the
decline of disability in carrying out life roles in the home and community. Some
studies did, however, provide an anecdotal account of individuals who experienced
an increase in ability to participate in daily life role functions.
Das and Park 23 used the Barthel index to assess improvements in self-care
independence in eight patients injected in their upper extremity musculature. Six
patients experienced greater independence in activities of daily living and self-care,
enabling them to more effectively carry out "typical" role functions.
Grazko and colleagues 29 offered two accounts of patients whose daily life role
functions changed after receiving BTX-A injections. First, a patient with traumatic
paraplegia complained of severe muscle spasms in the lumbar paraspinal region
causing reoccurring back pain. The patient was injected between the first and fifth
lumbar paraspinous muscles, where increased tone was located. The patient's
spasms were reduced significantly, from more than 10 spasms per week, to between
two to five spasms per week. Following four injections of BTX-A in a three month
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period, the patient demonstrated an "improvement in lifestyle". Second, a bedridden patient with advanced multiple sclerosis had severe spasticity of lower-limb
musculature. Based on results from the Degree of Adductor Tone Scale (see Table),
BTX-A injections decreased the patient's adductor tone from a "4" to a "2", and
enabled her to wear an adductor brace for the first time. The patient could then sit
upright in a chair, which had not been previously possible for several years.
Increased independence in life activities was described by several
researchers.3,4,31 Borg-Stein et aP discussed a patient who became more
independent in basic transfers after injection with BTX-A. Dunne et aPl reported
that treatment with BTX-A enabled five patients to walk again, thus encouraging
greater independence. Cosgrove et al 4 discussed a patient with athetoid cerebral
palsy who had particularly satisfying results after injection into the tibialis posterior
muscle. Preceding injection, the patient was unable to ambulate because of a
dynamic equinovarus deformity with forefoot adduction. Following injection, the
patient became able to position his foot plantigrade, producing a stationary foot for
weight-bearing and allowing independent ambulation for the first time.

CHAPTER 6
DISCUSSION AND CONCLUSION
Discussion
Clearly, injection of BTX-A into spastic muscles has been demonstrated to
decrease spasticity and hypertonia for the majority of individuals with multiple
sclerosis, cerebral palsy, spinal cord injury, spastic paraplegia, and spastic
hemiplegia. Based on the results obtained from a majority of studies, researchers
found significant decreases in spasticity based on qualitative data utilizing measures
such as the Oswestry scale, Degree of Adductor Tone Scale, and Ashworth scale.
This decrease in spasticity subsequently caused increased active and passive range
of motion, and decreased pain and uncontrolled movements in several cases.
To further our understanding of BTX-A and its effects on patients with spasticity,
it is necessary to go beyond the impairment dimension and the mere assessment of
movement using single-joint analysis. Patients often face the reality of their
impairments in the dimensions of functional limitations and disability, which few
researchers have considered in their studies. Several studies have attempted to
prove statistically that BTX-A injections improve gait and mobility, however, more
double-blind, placebo-controlled studies are necessary in these areas to quantify the
effects and val idate the cost effectiveness of BTX-A treatment.
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Two of the studies reviewed utilized intricate gait analysis techniques to quantify
the difference in gait dynamics following BTX-A injections. 4 ,28 Both studies
indicated substantial changes, enabling their patients to have more "normal" gait
patterns. Other researchers attempted to quantify changes in gait dynamics utilizing
a variety of measures, including the physicians rating scale, Lindmark's motor
assessment, Biodex evaluation, and PT evaluation/observation. Many patients
appeared to benefit from BTX-A injections, and demonstrated improved gait
patterns, "easier" ambulation, decreased scissoring, increased ability to clear the
foot during swing phase, increased ability to extend the knee and bear weight, and
increased balance. 3,27,29,31-33 Due to these positive preliminary results, researchers
have suggested the need for randomized, controlled clinical trials and detailed
documentation to define the proper role of BTX-A muscle injections in individuals
with spasticity.
The effects of botulinum toxin on disability in role functions is an area which has
been neglected in research studies. Few studies have mentioned the changes in
quality of life or the increased ability in carrying out life roles. This is an important
area to examine, and may help justify the use of BTX-A injections as a viable,
validated treatment. Of significant importance is quantifying the influence of
decreased impairment on the dimensions of function and disability. Hence,
information from these dimensions can be combined to expand our understanding
of the problem of spasticity and the effects of its resolution. 2
Critics of BTX-A therapy caution that before it is promoted as a "dramatic
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breakthrough" for patients with spasticity, larger randomized controlled trials are
needed. 37,38 Bleck 37 questioned how long patients can be cajoled into accepting
repeated injections over a period of a year or more. Neville38, professor of pediatric
neurology, wrote recently on the use of botulinum toxin for children with cerebral
palsy:
"If (further studies) confirm benefit, then botulinum toxin could
find several uses in the treatment of the cerebral palsies. These
include the modification of early patterns of axial asymmetry
that may influence later development of the spine and hips. It
could be used early to modify the effects of spasticity on soft
tissue and bone, thereby reducing the extent of later surgery.

It could also be used to mimic the effects of possible surgical
procedures. It could provide a time window for physical,
including orthotic, interventions ... and it could be used to treat
focal dystonias within the cerebral palsies, for which surgery
has gained such a bad reputation ... Botulinum toxin is
expensive and requires further studies combining careful
clinical and biomechanical delineation of specific problems
and methodological rigor."
During the consensus development held by The National Institute of Health
(N IH), suggestions were made for further areas of research for BTX-A treatment. 22
These included continued research in the following areas:
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"1. Study of the general properties of botulinum toxin including:
mechanism of action, metabolism and catabolism, mechanisms of
recovery from paralysis, the target receptors, pharmacology of other
serotypes, antidotes and blocking techniques, techniques to increase
the specificity and duration of action, stability and consistency of
pharmaceutical preparations.

2. Study of the indications for botulinum toxin treatment including:
efficacy and safety through controlled clinical trials that use reliable
outcome measures, optimal measures of clinical benefit, long-term
and remote effects, does/response relationships and dose schedules,
causes of primary failure, causes of secondary failure,
pathophysiology of the diseases treated, physiology of spasm
reduction in regional muscles that are not directly injected.
3. Study of contraindications for botulinum toxin treatment including:
pregnancy and lactation, high doses of chronic maintenance in infants
and children, diseases of neuromuscular transmission.

4. Study of the technique of injecting and handling of botulinum
toxin including: effects on location, dose, concentration, and volume
on response; dose selection based on objective physiologic or
anthropometric parameters; the value of EMG for diagnosis,
localization of the site(s) of administration, and control of dose.

36

5. Study of the side effects and complications of botulinum toxin
treatment including: antibody formation and its implications, longterm consequences of repeated injection, the variability in sensitivity
to injection among different patients and difference muscle groups in
an individual patient, the mechanism of undesirable regional effects,
valid and reliable parameters for assessment of outcome, systemic
effects."
The NIH emphasized that although botulinum toxin may help decrease the negative
effects of neurological symptoms (i.e. spasticity, uncontrolled movements, etc.), it is
not curative in nature.

Conclusion
Preliminary results from numerous studies have paved the road for additional
investigations involving BTX-A injections for individuals with spasticity. The data
accumulated from current research studies proved that botulinum toxin injections
are successful in treating the impairments associated with spasticity. Therefore,
research efforts need to be extended to the other dimensions of the NCMRR model
such as the effects of BTX-A injections on functional limitations and on disability in
role functions.
Research data has suggested that reducing muscle spasticity has the short-term
benefit of improving function and the long-term benefit of improving longitudinal
muscle growth. 4 ,s Although BTX-A injections may not permanently remove the
prospect of surgical intervention, they may delay surgery until the patient is older
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and at a lower risk for possible complications and recurrence of deformity.32

If

patients are able to obtain improved function, physical therapy following injection
of botulinum toxin may play an important role in helping clients recognize their
newly found skills and maximize the use of these abilities. Physical therapy may be
the key in helping patients gain benefit from botulinum toxin in the functional and
disability dimensions, and is another area that warrants additional research.
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